Are you living with ALS and would like to help in the search to find a cure?








What is the TUDCA-ALS Study?


The TUDCA-ALS study will look at a new drug called tauroursodeoxycholic acid (TUDCA).

The aim of the study is to determine whether TUDCA in combination with riluzole can slow the progression of ALS.

Patients of either gender, aged between 18 and 80, with a disease duration that is not exceeding 18 months, are eligible to take part in the study that will be conducted in 26 centres across 7 countries in Europe.



What is involved?



As part of the study you will be randomly assigned to receive either TUDCA or placebo. A placebo is a substance that contains no active drug, but is similar in appearance to the study drug. Both the TUDCA and the placebo capsules are provided in a dose of 4 capsules at a time and are to be taken twice a day.

You will take part in 9 visits to your TUDCA-ALS Centre over the 21 months you will be taking part in the study. During these visits a number of tests will be done, including having blood and cerebrospinal fluid samples taken.

How do I take part?

Sites recruiting for the TUDCA-ALS Trial are located in:

- <u>Italy</u>: Milano, Torino, Terni, Napoli
- Germany: Ulm, Berlin, Essen, Hannover, Jena, Dresden
- <u>UK</u>: Sheffield, Preston, Salford, Liverpool, Plymouth
- France: Tours, Limoges, Montpellier, Bordeaux
- Belgium: Leuven
- Netherlands: Utrecht
- Ireland: Dublin

To take part in this study, contact your national TUDCA-ALS Centre on Telephone Number: E-mail:

Website: <u>www.tudca.eu</u>

